Hanmi Pharm
Tracked across 5 events · 36 articles · First seen May 08, 2026 · Last active Sep 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Hanmi Pharm. Co., Ltd. entered into a licensing agreement with Eli Lilly and Company for sonefpeglutide, receiving an upfront payment of USD 75 million and potential milestone payments up to USD 1.185 billion, plus royalties. This significantly boosts its financial outlook and validates its LAPSCOVERY technology.
Jun 01, 2026 · 11 articles
Business
Impact: Hanmi Pharm, through its subsidiary North American Cobalt Inc., successfully acquired Aptose Biosciences, expanding its oncology pipeline.
Jun 30, 2026 · 6 articles
Business
Impact: Hanmi is the licensor, receiving USD 190 million upfront and up to USD 2.3 billion in total deal value. This validates its R&D capabilities and provides substantial financial upside.
Jul 20, 2026 · 7 articles
Tech
A study published on Sept. 17, 2026 in Science identified the inherited EGFR T790M mutation as a major risk factor for lung cancer, especially in never-smokers. Researchers led by Jaclyn LoPiccolo and Pasi A. Jänne…
Impact: Hanmi Pharm's terminated licensing deal with Boehringer Ingelheim for olmutinib is referenced, highlighting past difficulties in EGFR drug development.
Sep 17, 2026 · 6 articles
30
Boehringer Ingelheim paid $730 million Hanmi PharmEGFR T790M Inherited Lung...
ERGEN INTELLIGENCE
Track Hanmi Pharm live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard